March 2025 supplemental line of credit letter agreement providing up to $5.0 million, with convertible promissory notes and warrants; the full amount was drawn June 30, 2025.
| Officer | Age | In this role | Joined | Source |
|---|---|---|---|---|
|
Joel Lewis
Also a director
President and CEO
Title from the Form 4/A dated Jan 16, 2026
|
56 | Not stated | Not stated | |
|
Jack W. Callicutt
Chief Financial Officer
|
59 |
Since 2013
13 years
|
Not stated | |
|
Khurram Jamil
Chief Medical Officer
|
51 |
Since 2024
2 years
|
2024 |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
March 2025 supplemental line of credit letter agreement providing up to $5.0 million, with convertible promissory notes and warrants; the full amount was drawn June 30, 2025.
July 2025 supplemental line of credit letter agreement providing up to $10.0 million, with convertible promissory notes and warrants; the full amount was drawn December 31, 2025.
December 2025 supplemental line of credit letter agreement providing up to $10.0 million, with convertible promissory notes and warrants; undrawn as of June 30, 2026.
Conversion of all outstanding convertible promissory notes from prior credit facilities into 34,376,167 shares of common stock.
Loading...